Background: Little is known about the contribution of the invariant natural killer T (iNKT) cells in the onset of food allergy. Using a mouse model for cow’s milk allergy the function of iNKT cells was investigated. Methods: Mice were sensitized orally with casein or whey proteins. One hour before the sensitizations the mice were injected intraperitoneally with α-galactosylceramide (αGalCer) or control. One week after the last sensitization acute allergic skin reactions were measured. Furthermore, in the liver, spleen and mesenteric lymph nodes (MLN) percentages of iNKT cells were analyzed and liver lymphocyte restimulation assays were performed. Results: Whey- or casein-sensitized mice treated with αGalCer showed enhanced acute allergic skin reactions. The percentage of iNKT cells in the liver of sensitized mice was reduced compared to sham-sensitized mice. αGalCer treatment was found to deplete iNKT cells in the liver of sensitized as well as sham-sensitized mice, and these hepatocytes did not respond to ex vivo restimulation with αGalCer. αGalCer treatment did not reduce iNKT cell percentages in the spleen and MLN of sham-sensitized mice but abrogated the increase in iNKT cell percentage in the spleen upon whey sensitization, whereas it enhanced the iNKT cell percentage in the MLN of casein-sensitized mice. Due to the repeated application of αGalCer, livers were functionally depleted of iNKT cells. This resulted in an increased allergic effector response which was most pronounced in whey-sensitized mice and associated with enhanced whey-specific immunoglobulin levels. Conclusion: iNKT cells may suppress cow’s milk allergic symptoms in mice and may differentially regulate oral sensitization for casein and whey.

1.
Schafer T, et al: Epidemiology of food allergy/food intolerance in adults: associations with other manifestations of atopy. Allergy 2001;56:1172–1179.
2.
Host A: Frequency of cow’s milk allergy in childhood. Ann Allergy Asthma Immunol 2002;89(suppl 1):33–37.
3.
Rhodes HL, et al: Early life risk factors for adult asthma: a birth cohort study of subjects at risk. J Allergy Clin Immunol 2001;108:720–725.
4.
Schroeder A, et al: Food allergy is associated with an increased risk of asthma. Clin Exp Allergy 2009:39:261–270.
5.
Bahna SL: Cow’s milk allergy versus cow milk intolerance. Ann Allergy Asthma Immunol 2002;89(suppl 1):56–60.
6.
Kalach N, et al: Intestinal permeability in children: variation with age and reliability in the diagnosis of cow’s milk allergy. Acta Paediatr 2001;90:499–504.
7.
Tsuji NM, Kosaka A: Oral tolerance: intestinal homeostasis and antigen-specific regulatory T cells. Trends Immunol 2008;29:532–540.
8.
Mowat AM: Anatomical basis of tolerance and immunity to intestinal antigens. Nat Rev Immunol 2003;3:331–341.
9.
Kim HJ, et al: NKT cells play critical roles in the induction of oral tolerance by inducing regulatory T cells producing IL-10 and transforming growth factor beta, and by clonally deleting antigen-specific T cells. Immunology 2006;118:101–111.
10.
Delovitch TL: The ‘end of the beginning’ of the immunobiology of iNKT cells in health and disease. Int Rev Immunol 2007;26:1–3.
11.
Godfrey DI, et al: NKT cells: what’s in a name? Nat Rev Immunol 2004;4:231–237.
12.
Kronenberg M, Gapin L: The unconventional lifestyle of NKT cells. Nat Rev Immunol 2002;2:557–568.
13.
Park JE, et al: Fine specificity of natural killer T cells against GD3 ganglioside and identification of GM3 as an inhibitory natural killer T-cell ligand. Immunology 2008;123:145–155.
14.
Brutkiewicz RR: CD1d ligands: the good, the bad, and the ugly. J Immunol 2006;177:769–775.
15.
Gumperz JE, et al: Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med 2002;195:625–636.
16.
Oling V, et al: Circulating CD4+CD25 high regulatory T cells and natural killer T cells in children with newly diagnosed type 1 diabetes or with diabetes-associated autoantibodies. Ann NY Acad Sci 2007;1107:363–372.
17.
Ikarashi Y, et al: Phenotypical and functional alterations during the expansion phase of invariant Valpha14 natural killer T (Valpha14i NKT) cells in mice primed with alpha-galactosylceramide. Immunology 2005;116:30–37.
18.
Hachem P, et al: Alpha-galactosylceramide-induced iNKT cells suppress experimental allergic asthma in sensitized mice: role of IFN-gamma. Eur J Immunol 2005;35:2793–2802.
19.
Burdin N, et al: Selective ability of mouse CD1 to present glycolipids: alpha-galactosylceramide specifically stimulates V alpha 14+ NK T lymphocytes. J Immunol 1998;161:3271–3281.
20.
Matsuda H, et al: Alpha-galactosylceramide, a ligand of natural killer T cells, inhibits allergic airway inflammation. Am J Respir Cell Mol Biol 2005;33:22–31.
21.
Goto M, et al: Murine NKT cells produce Th17 cytokine interleukin-22. Cell Immunol 2009;254:81–84.
22.
Stronge VS, et al: A closer look at CD1d molecules: new horizons in studying NKT cells. Trends Immunol 2007;28:455–462.
23.
Lehuen A, et al: Overexpression of natural killer T cells protects Valpha14-Jalpha281 transgenic nonobese diabetic mice against diabetes. J Exp Med 1998;188:1831–1839.
24.
Saubermann LJ, et al: Activation of natural killer T cells by alpha-galactosylceramide in the presence of CD1d provides protection against colitis in mice. Gastroenterology 2000;119:119–128.
25.
Schmieg J, et al: Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-galactosylceramide. J Exp Med 2003;198:1631–1641.
26.
Kim HY, et al: The development of airway hyperreactivity in T-bet-deficient mice requires CD1d-restricted NKT cells. J Immunol 2009;182:3252–3261.
27.
Chang JH, et al: Functional maturation of lamina propria dendritic cells by activation of NKT cells mediates the abrogation of oral tolerance. Eur J Immunol 2008;38:2727–2739.
28.
Kim JO, et al: Asthma is induced by intranasal coadministration of allergen and natural killer T-cell ligand in a mouse model. J Allergy Clin Immunol 2004;114:1332–1338.
29.
Staden U, et al: Specific oral tolerance induction in food allergy in children: efficacy and clinical patterns of reaction. Allergy 2007;62:1261–1269.
30.
Niederberger V: Allergen-specific immunotherapy. Immunol Lett 2009;122:131–133.
31.
Skripak JM, Sampson HA: Towards a cure for food allergy. Curr Opin Immunol 2008;20:690–696.
32.
Schouten B, et al: Acute allergic skin reactions and intestinal contractility changes in mice orally sensitized against casein or whey. Int Arch Allergy Immunol 2008;147:125–134.
33.
Nowak M, Stein-Streilein J: Invariant NKT cells and tolerance. Int Rev Immunol 2007;26:95–119.
34.
Zeissig S, et al: Role of NKT cells in the digestive system. III. Role of NKT cells in intestinal immunity. Am J Physiol Gastrointest Liver Physiol 2007;293:G1101–G1105.
35.
Akbari O, et al: Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nat Med 2003;9:582–588.
36.
Liu TY, et al: Distinct subsets of human invariant NKT cells differentially regulate T helper responses via dendritic cells. Eur J Immunol 2008;38:1012–1023.
37.
Parekh VV, et al: Glycolipid antigen induces long-term natural killer T cell anergy in mice. J Clin Invest 2005;115:2572–2583.
38.
Sullivan BA, Kronenberg M: Activation or anergy: NKT cells are stunned by alpha-galactosylceramide. J Clin Invest 2005;115:2328–2329.
39.
Meyer EH, et al: Glycolipid activation of invariant T cell receptor+ NK T cells is sufficient to induce airway hyperreactivity independent of conventional CD4+ T cells. Proc Natl Acad Sci USA 2006;103:2782–2787.
40.
Askenase PW, et al: TLR-dependent IL-4 production by invariant Valpha14+Jalpha18+ NKT cells to initiate contact sensitivity in vivo. J Immunol 2005;175:6390–6401.
41.
Calbet JA, Holst JJ: Gastric emptying, gastric secretion and enterogastrone response after administration of milk proteins or their peptide hydrolysates in humans. Eur J Nutr 2004;43:127–139.
42.
Dangin M, et al: Influence of the protein digestion rate on protein turnover in young and elderly subjects. J Nutr 2002;132:3228S–3233S.
43.
Hall WL, et al: Casein and whey exert different effects on plasma amino acid profiles, gastrointestinal hormone secretion and appetite. Br J Nutr 2003;89:239–248.
44.
Toden S, et al: Differential effects of dietary whey, casein and soya on colonic DNA damage and large bowel SCFA in rats fed diets low and high in resistant starch. Br J Nutr 2007;97:535–543.
45.
Schouten B, et al: Contribution of IgE and immunoglobulin free light chain in the allergic reaction to cow’s milk proteins. J Allergy Clin Immunol 2010;125:1308–1314.
46.
Redegeld FA, et al: Immunoglobulin-free light chains elicit immediate hypersensitivity-like responses. Nat Med 2002;8:694–701.
47.
Redegeld FA, Nijkamp FP: Immunoglobulin free light chains and mast cells: pivotal role in T-cell-mediated immune reactions? Trends Immunol 2003;24:181–185.
48.
Groot Kormelink T, et al: Atopic and non-atopic allergic disorders: current insights into the possible involvement of free immunoglobulin light chains. Clin Exp Allergy 2009;39:33–42.
49.
Thio M, et al: Free immunoglobulin light chains: a novel target in the therapy of inflammatory diseases. Trends Pharmacol Sci 2008;29:170–174.
50.
van Esch BC, et al: Depletion of CD4+CD25+ T cells switches the whey-allergic response from immunoglobulin E- to immunoglobulin free light chain-dependent. Clin Exp Allergy 2010;40:1414–1421.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.